SilverOak Wealth Management LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

SilverOak Wealth Management LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 23.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 779 shares of the company’s stock after purchasing an additional 147 shares during the period. SilverOak Wealth Management LLC’s holdings in Eli Lilly and Company were worth $607,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd grew its position in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the period. GAMMA Investing LLC grew its position in Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after purchasing an additional 3,696 shares during the period. Finally, Warner Financial Inc. grew its position in Eli Lilly and Company by 129.2% in the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock worth $927,000 after purchasing an additional 633 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.0%

LLY opened at $818.45 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The firm’s fifty day moving average is $749.52 and its 200 day moving average is $766.23. The stock has a market cap of $774.63 billion, a price-to-earnings ratio of 53.49, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Guggenheim reiterated a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $939.12.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 in the last 90 days. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.